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Objective: The best current noninvasive surrogate for tumor biology is fluorodeoxyglucose positron emission
tomography (FDG–PET). Both FDG–PET maximal standardized uptake values and selected tumor markers
have been shown to correlate with stage, nodal disease, and survival in non–small cell lung cancer (NSCLC).
However, there are limited data correlating FDG–PET with tumor markers. The purpose of this study was to de-
termine the correlation of tumor marker expression with FDG–PET maximal standardized uptake values in
NSCLC.
Methods: FDG–PET maximal standardized uptake values were calculated in patients with NSCLC (n ¼ 149).
No patient had induction chemoradiotherapy. Intraoperative NSCLC tissue was obtained and tissue microarrays
were created. Immunohistochemical analysis was performed for 5 known NSCLC tumor markers (glucose trans-
porter 1, p53, cyclin D1, epidermal growth factor receptor, and vascular endothelial growth factor). Each tumor
marker was assessed independently by two pathologists using common grading criteria. Subgroup analysis based
on histologic characteristics and regional nodal status was performed.
Results: FDG–PET correlated with T classification (P< .0001), N stage (P ¼ .002), and greatest tumor dimen-
sion (P<.0001). In addition, increasing maximal standardized uptake values correlated with increased expression
of glucose transporter 1 (P<.0001) and p53 (P ¼ .04) in adenocarcinoma. Epidermal growth factor receptor ex-
pression correlated with maximal standardized uptake values without predilection for histologic subtype
(P ¼ .004).
Conclusion: FDG–PET maximal standardized uptake values correlate with an increased expression of glucose
transporter 1 and p53 in lung adenocarcinoma, but not squamous cell cancer. Future studies attempting to corre-
late FDG–PET with tumor biology will need to consider the effect of different tumor histologic types.Fluorodeoxyglucose positron emission tomography (FDG–
PET) has become an important tool in the armamentarium
of clinicians for diagnosing and staging of non–small cell
lung cancer (NSCLC). FDG–PETmaximal standardized up-
take values (SUVmax) of primary tumors have been shown
to correlate with both stage and nodal disease in NSCLC.1
Furthermore, tumor FDG–PET SUVmax have been shown
to predict survival in patients with NSCLC.2
Although the classic TNM staging system includes
widely known prognostic pathologic factors of NSCLC,
this system provides no assessment of the biologic or molec-
ular events leading to the development and progression of
lung cancer. Molecular pathology has provided considerable
information regarding the differential expression of gene
products associated with lung carcinogenesis. A recent
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doi:10.1016/j.jtcvs.2008.10.014The Journal of Thoracic andmeta-analysis of immunohistochemical studies investigating
tumor marker expression and its correlation to survival in
NSCLC found 17 significant tumor markers that have
been investigated by eight or more research groups.3 With
the advent of therapies directed at specific molecular path-
ways such as epidermal growth factor receptor (EGFR)
inhibitors and anti–vascular endothelial growth factor
(VEGF) antibodies, analysis of the relationship of molecular
markers to diagnostic methods, such as FDG–PET, used to
assess treatment response and to provide prognostic infor-
mation is clearly needed.
Although glucose metabolism is the central factor for
increased FDG uptake in tumor cells, very few studies have
investigated the correlation of FDG uptake with lung cancer
tumor marker expression. The 5 tumor markers selected
for evaluation in this study were glucose transporter 1
(GLUT-1), p53, EGFR, VEGF, and cyclin D1. We selected
these markers inasmuch as there is ample evidence in the
literature suggesting their importance in the development
and progression of lung cancer.4-13
The purpose of this study is to examine the correlation of
selective tumor marker expression to FDG–PET, the best-
known noninvasive surrogate marker of tumor biology.
We hypothesize that some or all of these 5 tumor markers
will correlate with SUVmax in NSCLC specimens. Sub-
group analysis of patients by locoregional nodal status andCardiovascular Surgery c Volume 137, Number 1 43
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CT ¼ computed tomography
EGFR ¼ epidermal growth factor receptor
FDG ¼ F-deoxyglucose
FDG–PET ¼ fluorodeoxyglucose positron
emission tomography
GLUT-1 ¼ glucose transporter 1
NSCLC ¼ non–small cell lung cancer
SUVmax ¼ maximal standardized uptake values
VEGF ¼ vascular endothelial growth factor
histologic characteristics will determine whether expression
patterns of the selected tumor markers and FDG–PET are
different. Collectively, these studies will offer insight into
the correlative relationships between expression of these
specific tumor markers and FDG–PET in NSCLC.
PATIENTS AND METHODS
Patients
Paraffin-embedded primary lung tumor samples and patient-matched
normal lung tissue in 149 consecutive patients were collected between Jan-
uary 2005 and October 2006. Approval for collection of the patient tissue
was obtained from the Institutional Review Board for Health Science Re-
search at the University of Virginia. Individual patient consent was ob-
tained for procurement of tissue for research purposes before patients
underwent surgery. Clinicopathologic data were collected from our general
thoracic surgery database. Of the 149 patients, 56% had their FDG–PET
scan performed and interpreted at the University of Virginia with a dedi-
cated fusion positron emission tomography/computed tomography (PET/
CT) scanner. The remaining 44% of patients had their FDG–PET imaging
performed at an outside institution with interpretation of the studies inde-
pendently performed by our nuclear radiologists at the University of
Virginia.
Preparation of the Tissue Microarrays
All tumor slides were reviewed for tumor type and grade by two pathol-
ogists. A representative slide and the corresponding block of formalin-
fixed paraffin-embedded tissue were selected. For each case, three 1-mm
cores of tumor and one core of uninvolved epithelium were removed
from the original block and embedded in a paraffin block with a specialized
manual arraying instrument (model MTA1; Beecher Instruments, Sun Prai-
rie, Wis).
Immunohistochemical Analysis
A tissue microarray was constructed for immunohistochemical studies
that evaluated p53, VEGF, EGFR, cyclin-D1, and GLUT-1. Information
for the antibody, antigen retrieval mechanism, and staining pattern are
shown in Appendix Table 1. Unstained tissue was used as the negative con-
trol. Positive controls are as follows: p53–human lymph node, EGFR–hu-
man placenta, GLUT-1–human red blood cells, cyclin D1–human tonsil,
and VEGF–colon cancer. Immunohistochemical staining was scored by cal-
culating the percentage of cells staining positive and by assessing the inten-
sity of immunohistochemical staining. Immunohistochemical intensity was
scored as 0¼ none, 1¼ weak, 2¼ moderate, and 3 ¼ intense. The product
of each tumor marker’s immunohistochemical staining was then calculated
by multiplying the percentage of positive cells by the staining intensity.14
Product scores ranged from 0% to 300%.44 The Journal of Thoracic and Cardiovascular SurgStatistical Analysis
Statistical analysis was performed with SAS version 9.1 for Windows
software (SAS Institute, Inc, Cary, NC). All P values were calculated
with the Spearman rank correlation test and the 2-tailed Student t test for
continuous variables.
RESULTS
One hundred forty-nine patients were included in this
study. The demographic characteristics of the population
are shown in Table 1.
Table 2 illustrates the selected tumor marker correlation
coefficients to SUVmax and the respective P values.
FDG-SUVmax correlated with greatest tumor dimension,
T classification, and N classification. There was a positive
correlation of increasing SUVmax and increased expression
of GLUT-1 and EGFR in all NSCLC samples. Figure 1 illus-
trates the expression patterns of these 2 tumor markers in pri-
mary lung cancer specimens. Cyclin D1, p53, and VEGF
expression did not correlate with SUVmax for our cohort
of patients.
NSCLC specimens were next stratified by histologic sub-
type (adenocarcinoma [n¼ 68] or squamous [n¼ 64]) to de-
termine whether the correlation of SUVmax to tumor
markers differed by tumor histology. Table 2 shows correla-
tion coefficients of SUVmaxwith the 5 tumormarkers for ad-
enocarcinoma and squamous carcinoma. In adenocarcinoma
specimens, GLUT-1 expression strongly correlated with
SUVmax, in contrast to squamous histology, inwhich no sig-
nificant correlation was found. Also, p53 was found to corre-
late with SUVmax in adenocarcinoma but not in squamous
carcinoma. Furthermore, EGFR expression, found to corre-
late with SUVmax in the entire cohort, did not reach statisti-
cal significance when stratifying by histologic subtype.
We next stratified all patents by FDG-SUVmax and
sought to determine whether there was a value that corre-
lated with a significant difference in tumor marker expres-
sion. These results are shown in Table 3. Given that
SUVmax less than 2.5 in lung tumors are less indicative of
TABLE 1. Patient demographics
Variable Value
Patients (N) 149
Median age (y) 69 (range, 36–88)
Sex (M/F) 79 (53%): 70 (47%)
Histology
Adenocarcinoma 68 (45.6%)
Squamous 64 (43.0%)
Large cell 11 (7.4%)
Bronchioloalveolar 6 (4.0%)
Pathologic stage
I 93 (62.4%)
II 35 (23.5%)
III 20 (13.4%)
IV 1 (0.7%)ery c January 2009
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STABLE 2. Correlation between FDG-SUVmax and tumor marker expression and pathologic stage in all patients with NSCLC (n ¼ 149), lung
adenocarcinoma (n ¼ 68), and squamous carcinoma (n ¼ 64)
All NSCLC specimens Adenocarcinoma Squamous
Correlation coefficient P value Correlation coefficient P value Correlation coefficient P value
Greatest tumor dimension 0.56 <.0001 0.36 .002 0.63 <.0001
T classfication 0.38 <.0001 0.28 .02 0.42 .0005
N classification 0.25 .002 0.26 .03 0.17 .18
GLUT-1 intensity 0.36 <.0001 0.38 .001 0.10 .42
GLUT-1 percent 0.36 <.0001 0.47 <.0001 0.07 .56
GLUT-1 product 0.37 <.0001 0.46 <.0001 0.07 .56
p53 intensity 0.10 .20 0.26 .03 0.14 .23
p53 percent 0.11 .16 0.23 .06 0.05 .66
p53 product 0.12 .14 0.25 .04 0.09 .50
EGFR intensity 0.20 .01 0.12 .32 0.18 .14
EGFR percent 0.24 .003 0.17 .16 0.19 .12
EGFR product 0.23 .004 0.15 .21 0.19 .12
Cyclin D1 intensity 0.06 .46 0.03 .79 0.009 .94
Cyclin D1 percent 0.13 .11 0.019 .87 0.07 .57
Cyclin D1 product 0.12 .13 0.03 .79 0.05 .69
VEGF intensity 0.02 .79 0.21 .08 0.13 .31
VEGF percent 0.03 .66 0.21 .08 0.11 .34
VEGF product 0.04 .58 0.24 .06 0.04 .38
GLUT-1, Glucose transporter 1; EGFR, epidermal growth factor receptor; VEGF, vascular endothelial growth factor.malignancy, we used these values as our control group.15
We noted a stepwise increase in the percentage of patients
with positive regional nodes who had increasing SUVmax.
GLUT-1 expression within tumor specimens was signifi-
cantly higher in patients with SUVmax greater than 10
compared with patients with SUVmax of 2.5 or less. Fur-
thermore, EGFR expression was found to be significantly
greater in patients with primary tumor SUVmax greater
than 2.5 compared with tumors with SUVmax less than 2.5.
The percentage of NSCLC that had expression of the se-
lected tumor markers and the corresponding mean SUVmax
based on regional nodal status is shown in Table 4. SUVmax
was significantly greater for tumors with regional node–pos-
itive disease (6.4 0.5 vs 8.5 0.6; P¼ .005). GLUT-1 ex-
pression was found in a significantly greater proportion of
tumors with associated regional nodal disease as compared
with GLUT-1 expression in tumors without nodal disease.
In the proportion of tumors demonstrating expression of
GLUT-1, p53, and cyclin D1, SUVmax was significantly
greater in the tumors with associated regional nodal disease
than in those with node-negative disease.
DISCUSSION
This study investigates the correlation of 5 tumor markers
in lung cancer with the best noninvasive method of assessing
tumor biology, FDG–PET. Previous studies have demon-
strated the correlation of FDG–PET SUVmax with survival
in patients with lung cancer.2,16
GLUT-1 overexpression, the human erythrocyte glucose
transporter, has been correlated with a poor prognosis in pa-The Journal of Thoracic and Ctients with lung cancer.17 Increased glucose uptake in tumor
cells is thought to be regulated by glucose transporter activ-
ity.5 In our study, SUVmax was found to positively correlate
with the expression of GLUT-1 in NSCLC and specifically
adenocarcinoma. These results support similar findings re-
ported in other studies.18,19 In addition, we demonstrated
that the percentage of positive GLUT-1 tumor cells was sig-
nificant higher between those patients with primary tumor
SUVmax greater than 10 when compared with those with
values less than 2.5. Stratifying this group of patients with
lung cancer by regional nodal status, we found that the num-
ber of lung cancers expressing GLUT-1 was significantly
higher in specimens with concurrent regional nodal disease.
Furthermore, SUVmax of these GLUT-1 positive tumors
with regional nodal disease was significantly greater than
SUVmax for node-negative tumors. One previous study
demonstrated a correlation of GLUT-1 expression in pri-
mary lung tumor with metastatic lymph nodes; however,
no comparison was made between GLUT-1 expression of
the tumor and its nodal status.20
Alterations of tumor suppressor genes such as p53 by mu-
tation or overexpression are frequently found in lung carci-
noma, with many studies, although not all, suggesting that
is associated with a poor prognosis.6,11,13 Our analysis of
p53 expression in NSCLC, demonstrated a significant
correlation of p53 overexpression with SUVmax in lung ad-
enocarcinoma. This is the first larger cohort study demon-
strating a correlation between p53 expression and SUVmax
in lung cancer. SUVmax of p53 immunopositive tumors
with regional nodal disease were significantly greater than
SUVmax for node-negative tumors. We did not findardiovascular Surgery c Volume 137, Number 1 45
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SFIGURE 1. NSCLC tissue microarray. A, Representative 23 magnification tissue microarray of GLUT-1 expression in NSCLC demonstrates differential
expression patterns between patient tumor samples. B, Representative 203 magnification illustrating diffuse GLUT-1 expression in NSCLC. C, Represen-
tative 103 magnification tissue microarray of EGFR expression in lung adenocarcinoma. D, Representative 103 magnification tissue microarray of EGFR
expression in lung squamous carcinoma. NSCLC, Non–small cell lung cancer; GLUT-1, glucose transporter 1; EGFR, epidermal growth factor receptor.a significant increase in the number of NSCLCs expressing
p53 on the basis of regional nodal status. Aberrant expression
of p53 in NSCLC has been associated with an increased like-
lihood of mediastinal nodal metastasis.21 The discrepancy
between our results and that study may be related to the 3-
fold higher representation of pathologic stage III and IV dis-
ease in that study.
EGFR expression appears to have moderate prognostic
value in NSCLC.9 Specific EGFR-activating mutations
within lung tumors have been associated with a dramatically
improved response to EGFR inhibitors in early-phase clini-
cal trials.22 EGFR expression was found to correlate to
SUVmax in the entire cohort; however, statistical signifi-
cance was not obtained when the specimens were examined
by histologic subtype. This discrepancy is likely a result of
the reduction in sample size associated with stratification.
Also, this study illustrated that EGFR expression was signif-
icantly greater in NSCLC with SUVmax greater than 2.5.
These results support the clinical utility of FDG–PET as
a means of assessing response to EGFR inhibitor therapy,
as suggested by other groups.22 We did not find a significant
difference in EGFR expression on the basis of tumor nodal
status. Additionally, SUVmax of EGFR-positive tumors
with regional nodal disease were not found to be greater
for similar tumors without nodal disease. Fontanini and as-
sociates23 found a correlation of EGFR expression in pri-46 The Journal of Thoracic and Cardiovascular Surgmary squamous cell lung cancers with the presence of
node-positive disease. However, this correlation was not
found in patients with lung adenocarcinoma. Our study
had an equal number of patients with squamous and adeno-
carcinoma histologic features, and there were fewer patient
samples examined, both of which may account for the dis-
crepancy between our study and that one.
Cyclin D1, an important cell cycle regulator, is translo-
cated to the cell nucleus when exposed to tobacco carcino-
gens, and this nuclear accumulation induces uncontrolled
cell proliferation.7 Cyclin D1 overexpression has been dem-
onstrated in NSCLC compared with normal lung tissue.4
SUVmax did not correlate with the expression of cyclin
D1. Other studies have reported similar findings.24 We
TABLE 3. FDG–PET SUVmax and tumor marker expression
SUVmax No.
Node
positive (%)
Immunohistochemistry
percent scores (mean ± SEM)
GLUT-1 (%) EGFR (%)
0–2.5 25 1/25 (4%) 28  6 reference 10  4 reference
2.5–5.0 37 10/37 (27%) 39  6 P ¼ .25 27  6 P ¼ .02*
5–10 53 20/53 (38%) 44  5 P ¼ .06 34  5 P ¼ .0003*
10 or greater 34 14/34 (41%) 65  6 P ¼ .0001* 37  7 P ¼ .002*
SUVmax, Maximal standardized uptake values; SEM, standard error of the mean;
GLUT-1,Glucose transporter 1; EGFR, epidermal growth factor receptor. *Two-tailed
Student t test, P< .05.ery c January 2009
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STABLE 4. Tumor marker expression and SUVmax by nodal status
Node-negative (n ¼ 104) Node-positive (n ¼ 45) P value
Tumor marker Percent positive (%) Mean SUVmax* Percent positive (%) Mean SUVmax* Percent positive (%) Mean SUVmax
GLUT-1 73 7.0  0.6 87 8.9  0.6 .03 .02
p53 75 6.4  0.5 78 8.3  0.7 .16 .03
Cyclin D1 81 6.3  0.5 78 8.4  0.6 .16 .01
VEGF 52 6.4  0.6 53 8.2  0.9 .14 .08
EGFR 52 7.6  1.0 49 8.8  1.9 .43 .28
SUVmax, Maximal standardized uptake values; GLUT-1, glucose transporter 1; VEGF, vascular endothelial growth factor; EGFR, epidermal growth factor receptor. *Mean 
standard error of the mean.also did not find a significant difference in cyclin D1 expres-
sion based on tumor nodal status. However, SUVmax in cy-
clin D1–positive tumors with regional node–positive disease
was significantly greater than in tumors without nodal dis-
ease. Cyclin D1 overexpression in NSCLC has been associ-
ated with lymph node metastasis.25 Closer inspection of
these data supports that cyclin D1 overexpression and nodal
disease were significantly stronger for stage III (P ¼ .001)
versus stage I or II (P ¼ .048) disease. In this study 41%
of patients had stage III disease, whereas in our study only
13% had stage III disease.
VEGF plays a critical role in tumor angiogenesis and
metastasis in NSCLC. Studies have demonstrated overex-
pression of VEGF in NSCLC.8,10 A recent review of angio-
genesis in NSCLC uncovered 16 studies highlighting the
prognostic significance of VEGF overexpression in lung
cancer.26 VEGF expression did not correlate with SUVmax
in our population. Our study is the first to define the relation-
ship of VEGF expression to FDG–PET in lung cancer.
Stratification by regional nodal disease found no significant
difference in VEGF expression based on tumor nodal status.
However, an insignificant trend favoring increased SUVmax
of VEGF-positive tumors with nodal disease compared
with similar tumors with node-negative disease was noted.
Previous studies investigating the correlation of VEGF
expression in NSCLC and the presence of nodal disease
have had discordant conclusions.27-30 Therefore, in this
complex milieu of growth factors, VEGF expression alone
in lung tumors is unlikely to predict the presence of lymph
node metastasis.
Limitations of this study include the limited sample size
used. A larger sample size may elucidate further relation-
ships between FDG–PET and the investigated tumor
markers. Second, use of tissue microarrays in which small
tissue cylinders are studied may not in fact adequately repre-
sent the entire specimen owing to tissue heterogeneity.
Third, despite our efforts to use a well-established protocol,
inherent drawbacks of immunohistochemical analysis in-
clude interlaboratory differences in antigen retrieval, stain-
ing protocols, and antibodies used. A fourth limitation is
that PET/CT imaging was performed on multiple scanners,
which could influence the interpretation of SUVmax. WeThe Journal of Thoracic andattempted to address this by having our nuclear radiologists
interpret the images at our institution.
Future study directions will evaluate expression of these
tumor markers at a transcriptional level using a more sensi-
tive method, quantitative real-time polymerase chain reac-
tion. This investigation will use cryopreserved lung
tumors, thereby circumventing the potential pitfall of using
paraffin-embedded tissue for the assessment of transcrip-
tional regulation.
In conclusion, GLUT-1 and EGFR expression in primary
NSCLC correlates with FDG-SUVmax. The correlation be-
tween SUVmax and GLUT-1 expression is significantly
stronger in lung adenocarcinoma. Additionally, p53 expres-
sion significantly correlated with SUVmax in lung adenocar-
cinoma. GLUT-1 expression in NSCLC is significantly
greater in patients with regional mediastinal nodal disease.
In tumors expressing GLUT-1, p53, and cyclin D1, SUV-
max was significantly greater in patients with regional nodal
disease. Finally, the correlation of EGFR expression with
FDG–PET in lung cancer suggests potential clinical utility
in monitoring response to EGFR inhibitor therapy. In con-
trast, a lack of correlation between FDG–PET and VEGF ex-
pression points to limited utility of FDG–PET to assess
clinical response of lung adenocarcinoma to anti-VEGF
therapies.
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